Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Sorry to see you go.
I can understand why as there was not much new in the update, but they didnt post anything negative at all. This will go up, not a matter of if, but when.
I have been doing this long enough to know to be patient. Ive sold a few times too early, only to see it skyrocket soon after.
Hope you have better luck with your next choice :)
Haven’t sold a share
The news today wasn’t bad - just not much new from it. Overall, all CBD and weed stocks were down today for the most part, so don’t be discouraged. They were all cooling off in their 4 day runs (KALY included.)
I am here for the big run up anyway. Heavily invested at a good price.
Shorts were in control today. Pretty simple to see on L2. Will be interesting to see just how much when the numbers are released tomorrow. Until that pressure from shorts is relieved OR we get news, gonna have a hard time running up big
The thing is, when she does run, you better already be locked and loaded or you're gonna miss out.
NEW NEWS!!!
***Everything new (not already in a prior PR) has been highlighted below***
Dallas, Tx – January 30, 2019 -- InvestorsHub NewsWire -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today released a corporate update that includes the latest on KALY’s developments with Puration, Inc, (USOTC: PURA) (“PURA”) and Generex Biotechnology, Inc. (OTCBB: GNBT), the company’s research on treatments for Chronic Obstructive Pulmonary Disease (COPD), and other updates. The comprehensive update is included in its entirety below:
Overview
Kali-Extracts, Inc. (“KALY”) is a health and wellness company set to generate revenue from its patented cannabis extraction technology through overlapping go-to-market strategies. KALY is utilizing is patented cannabis extraction process to develop numerous wellness products both internally and through partnerships. Similarly, KALY its patented cannabis extraction technology to develop pharmaceutical products internally and through partnerships.
Puration, Inc. (USOTC: PURA)
KALY has licensed its extraction process to PURA for the production of beverages. With over $1 million in trailing twelve-month sales, PURA’s sales of EVERx CBD Sports Water are growing. KALY is now working with PURA to formulate a 25 MG CBD formula for a new CBD infused water product. Together, PURA and KALY have signed over a $1 million agreement to produce CBD infused water for Generex Biotechnology, Inc. (OTCBB: GNBT). The GNBT product is expected to be on shelves soon.
Hemp4mula
KALY has introduced its own line of CBD infused candies under the name Hemp4mula. KALY has signed its first distribution agreement for Hemp4mula gum and initiated the production of Hemp4mula gummies. Hemp4mula gum will be on retail shelves soon and for sale on line soon.
Pharmaceuticals
Prior to KALY’s recent acquisition of NCM Biotech (NCM), NCM had conducted numerous trials on various treatment applications of extracts derived from their patented extraction process. KALY recently disclosed having completed an in vitro genomics study to evaluate the impact of its pharmaceutical grade cannabis extracts in combination with other therapies on Chronic Obstructive Pulmonary Disease (COPD) patients. Favorable results prompted the launch of a physiological study whose results will be released later this quarter. The World Health Organization estimates 65 million people worldwide are afflicted with moderate to severe COPD and GlobalData forecasts that the COPD treatment market will reach $14.1 billion by 2025. Other tests for other diseases to include cancer, have been conducted utilizing extracts from KALY’s patented extraction process. Shareholders can expect to see results from these various tests to be forthcoming soon in addition to next steps to advance the various potential treatments to production. KALY is actively working to develop partnerships with established, brand name pharmaceutical companies, to accelerate the further development of cannabis extract treaments.
Whoever came up with this "company update" should be fired.
They could at least hire a marketing expert who can give them basic advice NOT TO REHASH what everyone already knows in a press release. Doing so will only send the stock down.
Where is any information about extraction marketing in February? Retail developments? Where will the gummies and mints be sold? Where is their own CBD drink in development? Where is their own online website? How do they plan to generate revenue so they dont have to dilute? When will the CE get removed?
NEVER EVER send a press release that leads to more questions than answers.
https://www.investopedia.com/terms/d/daystocover.asp
Ratio on when they need to repay differs, but it is typically 3-4 days from when the shares were borrowed
SHORT VOLUME FOR KALY:
*If you look at the bold date of January 24th below, those are the shorters than have to cover by end of day today and why they are trying to drive this down (35 million shares shorted. 2nd highest amount in 30 days)
https://www.otcshortreport.com/company/KALY
Historical Short Volume Data for KALY
Date Close High Low Volume Short Volume % of Vol Shorted
Jan 29 NA NA NA 16,843,897 5,319,787 31.58
Jan 28 NA NA NA 20,758,999 8,804,644 42.41
Jan 25 NA NA NA 26,815,858 4,478,331 16.70
Jan 24 NA NA NA 69,440,561 34,782,820 50.09
Jan 23 NA NA NA 12,743,424 3,886,335 30.50
Jan 22 NA NA NA 15,782,491 6,814,858 43.18
Jan 18 NA NA NA 37,008,456 12,210,715 32.99
Jan 17 NA NA NA 76,971,684 37,583,389 48.83
Jan 16 NA NA NA 52,166,812 16,894,851 32.39
Jan 15 NA NA NA 60,387,023 13,967,217 23.13
Jan 14 NA NA NA 28,747,362 6,197,052 21.56
Jan 11 NA NA NA 20,122,896 8,053,882 40.02
Jan 10 NA NA NA 52,927,862 20,490,250 38.71
Jan 09 NA NA NA 53,277,348 25,500,686 47.86
Jan 08 NA NA NA 50,424,746 26,585,209 52.72
Jan 07 NA NA NA 50,349,666 27,343,137 54.31
Jan 04 NA NA NA 48,073,007 26,318,702 54.75
Jan 03 NA NA NA 25,995,101 10,893,761 41.91
Jan 02 NA NA NA 18,658,981 6,905,016 37.01
Dec 31 NA NA NA 51,154,612 24,698,845 48.28
Almost 2 million shorted in the last hour. Someone is betting against this big today
1 short seller has the block on at .0136 with 1.8 million
Bulls gotta break thru for the next leg up and to make them cover at a higher price
Buyer to seller ratio is about 75% to 25% today watching L2
Bulls are fighting against a few big short positions. Shorts are hoping its a "sell the news" event today so they make the most money possible
Dropping the price slowly on 10k bids
Looks like a bear trap.
First big buy will send this running.
NOUV = up 14%
GNBT = up 4%
PURA = up 3%
KALY = up 2%
All waiting on company update release today
Perfect time to get in before company update sends this much higher today
Obviously you must be new to trading. 1 big trade, or group of traders, can easily move a stock like this however they wish. Drop $100k tomorrow and see if this doesn't go crazy. I've seen it happen with penny stocks time and time again. One of those times was with a group who shorted KALY on Dec 20th, 2018.
If you are new to this stock, you shouldn't just read posts on iHUB and have them be the reason you decide to invest or not. Everyone should do their own DD.
After that DD step is taken, iHUB is a great place to share information and opinions (either side.) I know it has changed my opinion for the better a handful of times.
COMPANY NEWS COMING TOMORROW!!!
Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) announced an online corporate update scheduled for Wednesday January 30, 2019. The presentation will include updates on KALY’s developments with Puration, Inc, (USOTC: PURA) (“PURA”) and Generex Biotechnology, Inc. (OTCBB: GNBT). The presentation will also include updates on the company’s Hemp4mula product developments. The highlight of the presentation will feature the latest on the company’s research on treatments for Chronic Obstructive Pulmonary Disease (COPD). KALY has completed an in vitro genomics study to evaluate the impact of its pharmaceutical grade cannabis extracts in combination with other therapies on COPD patients. Favorable results prompted the launch of a physiological study whose results will be released later this quarter. The World Health Organization estimates 65 million people worldwide are afflicted with moderate to severe COPD and GlobalData forecasts that the COPD treatment market will reach $14.1 billion by 2025
They always want shares as cheap as possible before a big run
Nice 300k buy to take out .0129
MMs are held up at .0130 and .0131.....if we can break thru, wont be resistance till .0140+
Watching L2 shows some naked shorting going on
20k sitting on the bid at .0129 for 2 hours and over 300k+ slapped on the ask and the price doesnt/hasnt moved.
Someone comes in and sells 10k and it drops to .0126. Ha. So rigged. They do not want this running without their approval.
Agreed.
Great points.
Medical side is the main reason I invested here.
Also curious as to where they stand with GNBT and their RapidMist technology:
I believe our developing COPD therapies in combination with the potential for us to harness the patented RapidMist buccal cavity drug administration technology of Generex [Generex Biotechnology, Corp. (OTCQB: GNBT)] through our US Cannabis Health partnership, would put Kali-Extracts in front of any cannabis biotechnology company on the market. For that matter, I think Generex applying its patented RapidMist buccal cavity administration technology would bode well for Generex as well. I also happen to think that the combination of our COPD technology with the RapidMist technology of Generex would illustrate that GW Pharmaceuticals buccal drug administration is likely an infringement on Generex's RapidMist patent. In summary, the market has a lot yet to learn about Kali-extracts cannabis biotechnology. I hope the COPD example herein begins to give a glimpse of that yet to be relized value.
Also on their extraction franchise they are supposed to start marketing in February (how many interested, revenue, time, etc.)
Thank you for providing an actual fact.
Not that this will matter. He just hopes others believe his "only $500 were shorted" statement over solid evidence.
If you even researched for 5 minutes, you couldn't possibly miss the 2 different hemp4mula sales (which increased cuz they were so popular) or CBD contract with PURA (which increased because the waters are so popular. Now 10mg and 25mg.)
And thats the minimum guaranteed income we know about until they update us more tomorrow. Supposed to give a presentation on more retail items, pharmaceutical strides, and extraction franchise update.
Good try though!!!
Low volume and price increase
Looking good for an end of day run again
MAJOR NEWS UPDATE TOMORROW
"I believe the underlying value of Kali-Extracts cannabis biotechnology properties are as of yet unrecognized by the market," said Frederick Ferri, CEO of Kali-Extracts. "Doctors involved in research with our extracts have given me feedback that our extracts are superior to those of GW Pharmaceuticals [GW Pharmaceuticals, plc (NASDAQ: GWPH)]. As just one example of what our cannabis biotechnology can lead to, I believe our developing COPD therapies in combination with the potential for us to harness the patented RapidMist buccal cavity drug administration technology of Generex [Generex Biotechnology, Corp. (OTCQB: GNBT)] through our US Cannabis Health partnership, would put Kali-Extracts in front of any cannabis biotechnology company on the market. For that matter, I think Generex applying its patented RapidMist buccal cavity administration technology would bode well for Generex as well. I also happen to think that the combination of our COPD technology with the RapidMist technology of Generex would illustrate that GW Pharmaceuticals buccal drug administration is likely an infringement on Generex's RapidMist patent. In summary, the market has a lot yet to learn about Kali-extracts cannabis biotechnology. I hope the COPD example herein begins to give a glimpse of that yet to be relized value. Finally, I think the developing partnership between KALY and its other US Cannabis Health partners with Generex can put KALY, its other US Cannabis Health partners and Generex on top of their respective markets."
KALY has entered into a joint venture agreement named US Cannabis Health with Puration, Inc. (USOTC: PURA), and Nouveau Pharmaceuticals, Inc. (USOTC: NOUV) to combine their respective resources for the specific purpose of developing partnerships with major pharmaceutical companies to produce medical cannabis therapies.
It means they dont expect it to go any lower than .01, which is what investors want to see, and why its given a BUY rating
Worst case, you break even
Best case, you make 10x
KALY and PURA Receive BUY Recommendations From American Bulls - KALY Poised To Go $0.01 to $0.10 and PURA From $0.07 to $0.25
https://ih.advfn.com/stock-market/USOTC/kali-inc-KALY/stock-news/79139364/kaly-and-pura-receive-buy-recommendations-from-ame
KALY and PURA Receive BUY Recommendations From American Bulls - KALY Poised To Go $0.01 to $0.10 and PURA From $0.07 to $0.25
New York, NY -- January 29, 2019 -- InvestorsHub NewsWire -- via NextBigTicker.com (NBT) -- Kali, Inc. (USOTC: KALY) and Puration, Inc. (USOTC: PURA) have both today received BUY recommendations from AmericanBulls.com. Both companies have been turning in strong fundamental financial results in the rapidly evolving and expanding cannabis sectors. PURA has an upcoming new cannabis beverage launch in two weeks with West Coast Venture Partners (USOTC: WCVC) and North American Cannabis Holdings, Inc. (USOTC: USMJ), and KALY has a pending management update anticipated tomorrow to report the company’s latest developments to monetize its patented cannabis extraction process.
KALY
American Bulls Reported:
“Our system’s recommendation today is to BUY. The BULLISH HARAMI CROSSpattern finally received a confirmation because the prices crossed above the confirmation level which was at 0.0115, and our valid average buying price stands now at 0.0117.
Let’s jump on our white horses and go for a bullish ride. The bullish pattern that was previously identified is finally confirmed and a BUY signal is generated. Most probably, it is the right time to participate in bullish fervor. The market is telling you about a new profit. Do not miss this bullish opportunity.”
KALY has yet to be fully recognized for the potential of its patented process to deliver pharmaceutical therapies. As more research becomes available on the applications of the companies cannabis extracts to treat various diseases and conditions, the PPS has the potential to rocket past its 52 week $0.04 high to $0.10.
PURA
American Bulls Reported:
“Our system’s recommendation today is to BUY. The BULLISH PIERCING LINE pattern finally received a confirmation because the prices crossed above the confirmation level which was at 0.0720, and our valid average buying price stands now at 0.0762.”
Bullish Investor Reported:
“The stock price direction for the day for PURA is UP. The stock is experiencing a strong uptrend as of late, with an increase of more than 10 percent in the last three days. Based on BullishInvestor.com’s proprietary algorithms, PURA is currently signalling BULLISH … Overall the technical indicators are signaling a bullish reading for PURA. As such, it may be a wise decision to consider PURA at these price levels.”
PURA has a 52-week high PPS of $0.25 and a standing analyst report recommending a speculative buy and a $0.25 PPS. PURA has a number of major events in the works with the potential to trigger an rebound to the $0.25 52-week high PPS.
Learn more about the KALY at www.kali-extracts.com.
Learn more about PURA at www.purationinc.com.
Kaly is in a unique position:
1. They own the extraction patent. Plan to lease the extraction process out to hemp farmers
2. They plan on using their pharmaceutical grade CBD for medical research with COPD and asthma
3. They will use their process making retail products/drinks for PURA, GNBT, etc
4. They will use their process to make their own retail products (gummies, vapes, etc)
Major corporate update coming tomorrow
Chart setup looking good on the 1-day, 3-day, and 1-month timeframes
She should continue climbing now that the short volume is down and we are back over the SMA50
Watching for their scheduled news release on Wednesday to really get this moving
BIG NEWS COMING WEDNESDAY!!!
1. The presentation will include updates on the company's Hemp4mula product developments.
2. The highlight of the presentation will feature the latest on the company's research on treatments for Chronic Obstructive Pulmonary Disease (COPD). KALY has completed an in vitro genomics study to evaluate the impact of its pharmaceutical grade cannabis extracts in combination with other therapies on COPD patients. Favorable results prompted the launch of a physiological study whose results will be released later this quarter.
Nice buy there. Took down that wall.
Looking thin at the moment on L2.
Slap that ask and we might see a late day run and finally get back over SMA50
Looks like CSTI is the MM culprit keeping it just below SMA50
Keeps putting up a 1-2 million share wall every time it is gonna run and break over SMA50
Hopefully, it’s just them accumulating a ton of shares before letting her run up big
I wouldn’t be surprised to see a 30-50% 1-day gain at some point in the near future....maybe the day CE is officially removed, maybe with the right news Wednesday, etc.
MM throwing up that 2 mil ask wall early today
Accumulating shares cheap for them to let it rip at some point this week IMO
I got in early and big in KGKG as well
They are gonna be huge within 5 years. Holding long and strong.
KALY is more of a wildcard than Kona. With medical, retail and growing side, they could strike it huge here if done right. I am willing to take that risk vs. reward journey.
Kali Inc. (OTCPK:KALY) and Puration, Inc. (OTCPK:PURA) recently announced a THC extraction partnership. The two companies will combine efforts and resources in the extraction of THC for respective products to be produced by the two companies. PURA requires THC extract for its new THCSavor Beverage and KALY plans to produce THC extract for vapes. KALY owns a patented cannabis extraction process which PURA has licensed for specific purposes to include PURA's primary business, the production of cannabis infused beverages. Together, PURA and KALY plan to contract licensed extraction facilities in Colorado and California to produce THC under KALY's patented process and supervision. PURA and KALY, through their partnership, expect to optimize economies of scale in the production of high-quality THC extract.
https://www.bizjournals.com/prnewswire/press_releases/2018/12/19/enUK201812193026
Apologies if my posts come off harsh (they arent meant to be.)
I agree with your assessment. Really looking forward to what comes out on Wednesday from the medical side of things, as well as retail.
My best guess is that CBD laws in place prior to 2019 have caused roadblocks. I am hoping with new laws, they can now freely discuss future plans, along with what they have discovered working with Beech Tree Labs.
It is definitely a gamble here. I would never gamble on ex-CEO, but Mr. Ferri has a chance to do something special with Kaly. Will he? Wednesday will be a good indicator.
I have used a virtual address for my business many times.
IT IS COMMON!!!
For businesses that expand to new locations, they require local addresses. A virtual office address gives the business a local professional presence and a meeting location for clients and partners.
Not sure why you think this is some big smoking gun detective work.
KALY marina business doesnt exist anymore! NCM Biotech is becoming KALY. They do not have a corporate office in Texas. They are located in Rhode Island.
CBD just became legal this month with the new Farm Bill. This is a long hold and at the very beginning stage. Their growth is a risk you are gambling on as an investor. If you are looking to get rich this week, this is NOT the company for you.
Look at MacD and RSI
We also bounced off of .0103 three times
Finally, look at the accumulation chart. Someone has been loading big the last week (not just me.)
All 4 of these are indicating a reversal
I appreciate you sharing this information
But it doesn't change my view on this company one bit. The EX-CEO was based in Florida and for whatever reason, needs a virtual address in Texas (I assume in order to do business easier with PURA and NOUV based there.)
I own and operate a 7 figure business and I have virtual addresses all over the country for various reasons. If someone doesn't want to do business with me over my physical location being in a different state, so be it. Where I am located does not affect business one bit (except for taxes and healthcare mainly.)
The real concern is NCM Biotech, not Kaly HQ. Trying to reach out to the old Kaly makes no sense to me as none of them have stayed on as employees of new Kaly except for the ex-CEO as a business advisor.
Try contacting NCM Biotech (new KALY), their management, and look into their vision. They own the CBD patent, process, and retail items to come. They are the ones to reach out for answers to your questions.
If my investment was based off ex-Kaly CEO and the failed marina business, I would have never invested here. Instead, I have complete faith in CEO Frederick Ferri, Lloyd R. Saberski, M.D.,
Yale University, John N. Gaitanis, MD., and John McMichael, Ph.D., President & CEO Beech Tree Labs.
Here is an excerpt from Beech Tree Labs:
BTL-slo addresses a broad range of respiratory diseases such as chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF). According to WHO, 65 million people have moderate to severe COPD with 3 million deaths annually. Approximately five million people worldwide suffer from IPF with a 50 percent mortality rate within three years of diagnosis. The incidence of these disorders is steadily increasing.
Market Impact: Beech Tree Labs is focusing its efforts on BTL-slo for the treatment of COPD, a market currently estimated to be $5 billion in the United States and $11 billion worldwide. Some observers estimate that COPD is grossly under-diagnosed and that the market would grow significantly if improved therapeutic agents with less severe side effects were introduced as side effects prevent many COPD patients from using currently approved drugs.
Safety: Dose levels of up to 5,000X the anticipated human dose of the streptolysin O component have been administered daily by tail vein injection in rats for seven days without adverse effects. BTL-stcf, microdose DNA, has been evaluated in three FDA-authorized clinical trials for various respiratory conditions, including COPD, with no serious adverse effects reported.
Efficacy: The anti-scarring properties of BTL-slo are evident from genomic, cellular, tissue, pre-clinical animal studies.
Mechanism of Action: Unlike many drugs in development for COPD, Beech Tree Lab’s product candidate is new and innovative, not simply a me-too product. Our product may consist of BTL-slo (Streptolysin O, a 60kD peptide and one of a group of filterable hemolysins derived from Group A beta-hemolytic streptococci) as a single agent or used together with BTL-stcf. This combination provides a new treatment paradigm for a wide range of debilitating pulmonary diseases.
Intellectual Property: A U.S. patent has been issued for treatment of COPD. Applications of the foreign counterparts of this patent have been filed. Additional new patents are being submitted and prosecuted by Beech Tree for the treatment of adhesions, lung diseases, and various other scar-associated indications.
Our experiments, studies, and case reports provide compelling evidence of significant efficacy of BTL-slo/stcf in treating lung diseases like COPD, as well as likely mechanism of action through which described clinical outcomes are achieved.
-------------------BIG THINGS ARE COMING!!!
https://ih.advfn.com/stock-market/USOTC/kali-inc-KALY/stock-news/79121777/kaly-kali-extracts-copd-research-targeting-14-b
KALY - Kali-Extracts COPD Research Targeting $14 Billion Treatment Market To Be Featured In Online Corporate Update Next Week
Print
Alert
Dallas, TX -- January 25, 2019 -- InvestorsHub NewsWire -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today announced an online corporate update scheduled for Wednesday next week on January 30, 2019. The presentation will include updates on KALY’s developments with Puration, Inc, (USOTC: PURA) (“PURA”) and Generex Biotechnology, Inc. (OTCBB: GNBT). The presentation will also include updates on the company’s Hemp4mula product developments. The highlight of the presentation will feature the latest on the company’s research on treatments for Chronic Obstructive Pulmonary Disease (COPD). KALY has completed an in vitro genomics study to evaluate the impact of its pharmaceutical grade cannabis extracts in combination with other therapies on COPD patients. Favorable results prompted the launch of a physiological study whose results will be released later this quarter. The World Health Organization estimates 65 million people worldwide are afflicted with moderate to severe COPD and GlobalData forecasts that the COPD treatment market will reach $14.1 billion by 2025.
We made a new higher low today on low volume = positive!!!
We almost cleared the SMA50 a handful of times today as well
Looks like we may be breaking out of the downward momentum heading into the big company update on Wednesday
See you guys on Monday :)
MMs are working overtime to keep this down today.
Typical manipulation
When they finally decide to walk KALY up instead of down, she is gonna run big
Held up well today over lunch
Watching to see if this can hit SMA50 by close today
Will MMs hold her back or let her fly?
NCM Biotech may or may not lay out a revenue stream during their call next week
They mentioned in the PR an update on their gummies/mints/etc as well
Without a revenue stream, it is clear why they have been diluting
They have alot to turn around, starting with the CE, but it is all very doable, and in the near term
Just need hard figures on their business plan for 2019:
1. How many/Who are interested in their extraction patent?
a. How much do they make per month for franchise revenue per agreement?
2. How far along are they on Medical CBD research/trials using their extraction process for COPD/Asthma/etc.? And how do they plan on revenue from the research? Any new medical patents?
a. How do they plan on raising funds for further research/trials without diluting?
3. What CBD water/tea/etc do they plan on releasing under their own brand? Or are they just planning on extracting for other companies? (PURA, GNBT, etc.)
4. What marketing do they have in place for future hemp farmers finding them and using their extraction process?